To reach the next value inflection
LicenseRx asset brief
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Probability of Success
14% · grade C · Medium data confidence
Model PoS 14% (grade C, medium data confidence). Strongest signals: Indication pull, Competitive whitespace. Biggest drag: IP position.
Data maturity (22%)
41
Early / Discovery; human data.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
55
Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.
Indication pull (14%)
77
Oncology, Immunology -- active buyer appetite.
Competitive whitespace (12%)
78
Under-served segment; crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
62
Public evidence mentions: human, patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →